Davita Inc vs Norfolk Southern Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Norfolk Southern Corporation trades at $317.24 (market cap $70.35B). The key difference: Norfolk Southern Corporation is far larger — about 6.2× Davita Inc's market cap, and Norfolk Southern Corporation pays a 1.72% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Norfolk Southern Corporation for 33 Days on average.
| DVA | NSC | |
|---|---|---|
Market Cap | $11.28B | $70.35B |
Volume | 650,294 | 825,542 |
Sector | Health | Industrials |
52-Week High | $240.96 | $352.98 |
52-Week Low | $103.87 | $278.19 |
Typical Hold Time | 113 Days | 33 Days |
Enterprise Value | $24.00B | $85.89B |
Dividend Yield | — | 1.72% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Norfolk Southern (NSC) trades at $313.20, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.52 exceeding expectations by 6%. Valuation metrics include P/E of 26.72 and ROE of 16.97%, while the proposed Union Pacific merger progresses through regulatory review. Cash flow trends show operational strength with $4.36B from operations in 2025.
Outlook remains constructive with 43.75% analyst buy ratings and $361.86 consensus target offering 15.5% upside. Key risks include merger approval uncertainty and fuel cost pressures. The combination creates transcontinental railroad opportunities but faces STB regulatory hurdles. Earnings on October 22, 2026 will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →